

Referenser

1. Johnell O, Gullberg B, Allander E, Kanis JA. The apparent incidence of hip fracture in Europe: a study of national register sources. *Osteoporos Int.* 1992;2:298-302.
2. Eklund F, Nordstrom A, Neovius M, Svensson O, Nordstrom P. Variation in fracture rates by country may not be explained by differences in bone mass. *Calcif Tissue Int.* 2009;85(1):10-16.
3. Michaëlsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL. Genetic liability to fractures in the elderly. *Arch Intern Med.* 2005;165(16):1825-1830.
4. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis *N Engl J Med.* 1992;327:620-627.
5. Kharazmi M, Hallberg P, Schilcher J, Aspenberg P, Michaelsson K. Mortality After Atypical Femoral Fractures: A Cohort Study. *J Bone Miner Res.* 2016;31(3):491-497.
6. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int.* 1994;4(6):368-381.
7. Jarvinen TL, Michaelsson K, Aspenberg P, Sievanen H. Osteoporosis: the emperor has no clothes. *J Intern Med.* 2015;277(6):662-673.
8. Jarvinen TL, Michaelsson K, Jokihaara J, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. *BMJ.* 2015;350:h2088.
9. Fleisch H. Development of bisphosphonates. *Breast Cancer Res.* 2002;4(1):30-34.
10. Svedbom A, Hernlund E, Ivergard M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. *Archives of osteoporosis.* 2013;8(1-2):137.
11. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev.* 2008(1):CD004523.
12. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev.* 2008(1):CD001155.
13. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev.* 2008(1):CD003376.
14. McClung M, Boonen S, Topping O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. *J Bone Miner Res.* 2011.
15. Curtis JR, Delzell E, Chen L, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. *J Bone Miner Res.* 2011;26(4):683-688.
16. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. *J Bone Miner Res.* 2008;23(9):1435-1441.
17. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. *JAMA internal medicine.* 2015;175(6):913-921.
18. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 2016;31(1):16-35.
19. Grey A, Bolland MJ. The effect of treatments for osteoporosis on mortality. *Osteoporos Int.* 2013;24(1):1-6.

20. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007;357(18):1799-1809.
21. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. *J Bone Miner Res*. 2010;25(1):91-97.
22. Jarvinen T, Michaelsson K, Jokihaara J, et al. Authors' reply to Lee and colleagues. *BMJ*. 2015;351:h3737.
23. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA*. 2010;303(12):1180-1187.
24. Abraha I, Cherubini A, Cozzolino F, et al. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. *BMJ*. 2015;350:h2445.
25. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. *Circulation*. 1981;64(4):669-673.
26. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ*. 2001;323(7303):42-46.
27. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.
28. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. *N Engl J Med*. 2014;371(10):974-976.
29. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. *Acta Orthop*. 2015;86(1):100-107.
30. Ulmner M, Jarnbring F, Topping O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*. 2014;72(1):76-82.
31. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. *Epidemiol Rev*. 1997;19:244-257.
32. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int*. 2006;17(12):1726-1733.
33. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. *Pharmacoepidemiol Drug Saf*. 2012;21(3):297-304.
34. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. *Mayo Clin Proc*. 2006;81(8):1013-1022.
35. Leavy B, Michaelsson K, Aberg AC, Melhus H, Byberg L. The Impact of Disease and Drugs on Hip Fracture Risk. *Calcif Tissue Int*. 2017;100(1):1-12.
36. Byberg L, Gedeberg R, Cars T, et al. Prediction of fracture risk in men: a cohort study. *J Bone Miner Res*. 2012;27(4):797-807.
37. Collins GS, Michaelsson K. Fracture risk assessment: state of the art, methodologically unsound, or poorly reported? *Curr Osteoporos Rep*. 2012;10(3):199-207.
38. Jarvinen TL, Jokihaara J, Guy P, et al. Conflicts at the heart of the FRAX tool. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2014;186(3):165-167.
39. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. *Osteoporos Int*. 2008;19(4):385-397.
40. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. *Bone*. 2009;44(5):734-743.
41. Ford N, Norris SL, Hill SR. Clarifying WHO's position on the FRAX(R) tool for fracture prediction. *Bull World Health Organ*. 2016;94(12):862.

42. Hillier TA, Cauley JA, Rizzo JH, et al. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? *J Bone Miner Res*. 2011;26(8):1774-1782.
43. Ensrud KE, Lui LY, Taylor BC, et al. A comparison of prediction models for fractures in older women: is more better? *Arch Intern Med*. 2009;169(22):2087-2094.
44. Masud T, Binkley N, Boonen S, Hannan MT, Members FPDC. Official Positions for FRAX(R) clinical regarding falls and frailty: can falls and frailty be used in FRAX(R)? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). *J Clin Densitom*. 2011;14(3):194-204.
45. Kanis J, Group obotWHOS. *Assessment of osteoporosis at the primary health-care level*. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield;2007.
46. Järvinen TLN, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. *BMJ*. 2008;336(7636):124-126.
47. Harvey NC, Oden A, Orwoll E, et al. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. *J Bone Miner Res*. 2017.
48. Wagner H, Melhus H, Gedeberg R, Pedersen NL, Michaelsson K. Simply ask them about their balance--future fracture risk in a nationwide cohort study of twins. *Am J Epidemiol*. 2009;169(2):143-149.
49. Lang T, Cauley JA, Tylavsky F, et al. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. *J Bone Miner Res*. 2010;25(3):513-519.
50. Moore AZ, Caturegli G, Metter EJ, et al. Difference in muscle quality over the adult life span and biological correlates in the Baltimore Longitudinal Study of Aging. *J Am Geriatr Soc*. 2014;62(2):230-236.
51. Cederholm T, Cruz-Jentoft AJ, Maggi S. Sarcopenia and fragility fractures. *European journal of physical and rehabilitation medicine*. 2013;49(1):111-117.
52. Uusi-Rasi K, Patil R, Karinkanta S, et al. Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. *JAMA internal medicine*. 2015;175(5):703-711.
53. El-Khoury F, Cassou B, Charles MA, Dargent-Molina P. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2013;347:f6234.
54. Stattin K, Michaelsson K, Larsson SC, Wolk A, Byberg L. Leisure-Time Physical Activity and Risk of Fracture: A Cohort Study of 66,940 Men and Women. *J Bone Miner Res*. 2017;32(8):1599-1606.
55. Grey A, Bolland M. Web of industry, advocacy, and academia in the management of osteoporosis. *BMJ*. 2015;351:h3170.
56. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. *BMJ*. 2017;356:i6770.
57. Bero L. Industry sponsorship and research outcome: a Cochrane review. *JAMA internal medicine*. 2013;173(7):580-581.
58. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. *Cochrane Database Syst Rev*. 2017;2:MR000033.